Company intelligence / Profile preview

BlueAllele

Oakdale, Minnesota, United Statesblueallele.com ↗

Ownership: Private
Development stage: Preclinical

Overview

BlueAllele has developed patented gene editing technologies focused on single-dose in vivo treatments for genetic diseases. Their PALIDON platforms are designed to enable precise, durable corrections via the NHEJ pathway. The company holds multiple US patents covering their core technology but has not yet reported clinical trial results or advanced candidates into human studies

Therapeutic areas: Metabolic DisordersRare DiseasesHematologyOphthalmologyNeurology
Modalities: Gene editing templates (repair templates)gene therapy vectors
Industry: Biotech

Beyond the preview

Go deeper on BlueAllele.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BlueAllele.

Explore the full profile